Regeneron Pharmaceuticals, Inc.
REGN
Below: live stock price for Regeneron Pharmaceuticals, Inc. (REGN), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Regeneron Pharmaceuticals, Inc. (REGN) trades at 840.86 USD on investpig.
- Prev close
- $852.03
- Volume (24h)
- $99.30M
- Market cap
- $86.57B
- Currency
- USD
Score
Insufficient data
- Value—
- Quality—
- Momentum—
- Growth—
- Risk—
- Dividend—
- Liquidity—
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 862.1972 +2.54%
- +20 bars
- 892.5293 +6.14%
- +60 bars
- 904.5479 +7.57%
- +120 bars
- 904.9917 +7.63%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.033 USD.
Interpretation
Price sits near the upper third of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Price report
How this asset has actually moved over the last 253 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 33.4%
- Max drawdown
- -26.1%
- Below period high
- -2.2%
- Best day
- +11.82%
- Worst day
- -9.82%
- Up days
- 51%
- Current streak
- 1 down
- Typical day swing
- 2.7%
- Volume vs average
- -18%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 859.34 high → 594.9 low · 60 bars
- ResistanceFib +161.8% extensionnot reached1,287.2 USD+53.08% from current
- ResistanceFib +100% extensionnot reached1,123.78 USD+33.65% from current
- ResistanceFib +61.8% extensionnot reached1,022.76 USD+21.63% from current
- ResistanceFib +27.2% extensionnot reached931.2677 USD+10.75% from current
- Current840.86 USD
- SupportFib 23.6% retracementNearesttested 8×796.9322 USD-5.22% from current
- SupportFib 38.2% retracementtested 3×758.3239 USD-9.82% from current
- SupportFib 50% midpointtested 2×727.12 USD-13.53% from current
- SupportFib 61.8% retracementtested 3×695.9161 USD-17.24% from current
- SupportFib 78.6% retracementtested 5×651.4902 USD-22.52% from current
- SupportFib −27.2% extensionnot reached522.9723 USD-37.81% from current
- SupportFib −61.8% extensionnot reached431.4761 USD-48.69% from current
- SupportFib −100% extensionnot reached330.46 USD-60.70% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Recent news
- Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?Barchart1d ago
- Regeneron Seen Weighing Expanded Sanofi Deal, RBC SaysMT Newswires1d ago
- 2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCBGlobeNewswire1d ago
- Heart-Drug Breakthroughs Can’t Stop Biotech Stocks From SlidingBarrons.com1d ago
- Trump Announces Drug Pricing Deals with Teva, 8 Other CompaniesBarrons.com2d ago
- Regeneron Pharmaceuticals (REGN) As Pasatru Approval Tests An Undervalued ViewSimply Wall St.4d ago
- Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOPSimply Wall St.4d ago
- Non-Melanoma Skin Cancer Market: Focus on Disease Indication, Treatment Type, Country and Region, 2025-2035GlobeNewswire3d ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,754 USD+1.90%
- 7203.TToyota Motor Corporation3,117 USD-0.51%
- 9984.TSoftBank Group Corp.5,001 USD+1.56%
- 6758.TSony Group Corporation3,895 USD-0.64%
- 6861.TKeyence Corporation77,980 USD-0.05%
- NVDANVIDIA Corporation226.145 USD+0.77%
- AAPLApple Inc.329.42 USD+1.37%
- GOOGLAlphabet Inc.341.435 USD+1.28%
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.